NNMT is an enzyme that methylates nicotinamide (a form of vitamin B3), converting it to N1-methylnicotinamide and effectively removing it from the NAD+ salvage pathway
It should be noted that the musculoskeletal evidence base remains preclinical, a 2025 scoping review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine found no adequately powered randomised controlled trials
Overall, the deposition fraction for the LoS was on an average 8.0-fold higher than the CU deposition fraction, with the corresponding subject-specific improvement range being 1.815.8 folds for the five test models
Typical injectable GHK-Cu dose ranges Standard starting dose: 1 mg per day subcutaneous Conservative / beginner dose: 0.5 mg per day Intensive / wound-healing dose: 23 mg per day Upper research range: 4 mg per day (rarely exceeded) Frequency: once daily, or split into morning + evening microdoses for steadier levels Route: subcutaneous (SC) injection - typically abdomen , thigh or flank
It is important to note that this alteration not only potentially increases its stability but also may affect how it interacts with other cellular components compared to its natural counterpart